BioPharma & Research
Most precision oncology pipelines rely heavily on DNA sequencing and digital pathology. But these methods often miss crucial information: whether a gene mutation is actually driving biological activity.
Wren Laboratories fills this gap with our proprietary mRNA-based liquid biopsy platform, delivering real-time insights into gene expression, signal pathway activity and tumor dynamics.
By integrating our breakthrough mRNA technology into your drug discovery efforts, you can better:
- Identify mutations that are biologically active—not just present
- Predict therapeutic efficacy and safety with greater clarity
- Accelerate development of targeted diagnostics and treatments
Why Partner with Wren Laboratories?
- Exclusive sample stabilization technology: Whole blood and saliva mRNA preserved for ≥10 days at ambient temperature
- Ultra-low volume requirements: Just 0.2 mL of blood per test
- Results in as little as 3–5 days for prospective studies
With deeper insights into tumor biology, your therapeutic pipeline becomes smarter, faster, and more targeted.
Innovative Biomarker Solutions
With over 115 national and international patents and 60+ clinical validation studies involving 70+ investigators from 45 leading medical institutions, we provide cutting-edge biomarker and precision medicine solutions for biopharma and biomedical researchers.
Current Challenges in Oncology Drug Development
-
Communication Gaps
Misalignments between the pharmaceutical and diagnostic industries lead to inefficiencies.
-
Focus on DNA and Proteomics
Advances in NGS and digital pathology have largely overlooked mRNA gene expression approaches.
-
Genomic Analysis Shortcomings
Current analyses often miss valuable insights by focusing on single mutations or broad datasets.
-
Transcription Issues
The predictive power of DNA mutation profiling in cancer can be limited.
-
Liquid Biopsy Challenges
Most assays focus on single blood components, which do not capture the complete tumor status.
-
mRNA Instability
The sensitivity of mRNA presents logistical challenges for accurate results.
-
Tissue Sample Limitations
Tumor tissue analysis can yield misrepresentative data due to heterogeneity and quality issues.
-
CRO Performance
Many contract research organizations (CROs) fall short of industry expectations.
Wren’s Solutions for BioPharma
Industry
Expertise
With extensive experience working with local and global CROs, we are dedicated to delivering the pharma triad: quality, efficiency, and competitive pricing in biomarker and companion diagnostic (CDx) services.
Liquid Biopsy
Specialization
Our validated liquid biopsy mRNA multi-gene expression assays have been used in over 60 clinical studies, collaborating with more than 70 key opinion leaders from top institutions worldwide.
Comprehensive
Analysis
We analyze mRNA from whole blood, capturing signals from cfRNA, exosomes, and circulating tumor cells (CTCs) for a more accurate representation of tumor content and immune response.
Analytical
Robustness
Our PCR-based assays are over 100 times more sensitive than RNASeq. Utilizing carefully selected gene panels, the assays have unmatched sensitivity and specificity.
Logistics Are
Made Easy
Our proprietary mRNA stabilization tubes maintain RNA viability for at least 10 days at room temperature and up to 6 years at -80°C, outperforming standard collection tubes. This allows for minimal blood or saliva samples (just 0.2 mL) for analysis.
Data Outputs
Our data is straightforward, customizable, and includes:
-
Binary Readout
Positive/negative results based on clinically validated cutoffs, ideal for patient selection.
-
Monitoring Scores
Changes in ML numerical scores for tracking minimal residual disease (MRD) or tumor recurrence.
-
Raw Data
Raw PCR data is provided to enable sub-panel analyses
-
Visualization Tools
Gene clustering, heatmaps, volcano plots, and more.
Biomarker Assay Offerings
We offer a variety of multi-gene expression assays, including:
-
CLIA, CAP, and NYS-Approved Blood mRNA Assays
– NETest®: Detects neuroendocrine differentiation in solid tumors (lung, prostate, colon).
– PROSTest®: Designed for prostate cancer.
-
Research Use Only (RUO) Assays
– Saliva assays for NET and prostate cancer.
– Whole blood and saliva assays for lung, pancreas, colorectal, breast, melanoma, and multiple myeloma.
-
Custom Solutions
Tailored mRNA gene panels for oncology, immunology, and more.
Scope of Services
Discovery & Translational Research
Biomarker/Target Discovery: Utilize our gene signatures and advanced analytics to identify and validate novel biomarkers.
POC, POM and PD: Our regulated biomarkers serve as efficacy endpoints, while our RUO assays support exploratory studies.
Patient
Monitoring
MRD Detection: Identify minimal residual disease or tumor recurrence in oncology trials.
Early Detection: Monitor neuroendocrine tumor development in non-oncology trials with potential carcinogenic drugs.
Patient Selection & Stratification
Laboratory-Developed Tests (LDT): For early-phase trial patient selection.
Regulated IUO: Support for companion diagnostic (CDx) development.
Operations Made Easy
Blood Collection Tubes
Our RNA stabilization tubes ensure mRNA stability for at least 10 days, allowing for global ambient shipping.
Dedicated Project Management
Every sample matters. We track all kits and shipments closely, with an experienced project manager overseeing each study.
Eliminate Preanalytical Work
Extracting just 0.2 mL of whole blood avoid the need for sample processing and its associated preanalytical variabilities.
Quick Turnaround Time
For real-time analysis, we provide results within 3 days, and custom assay can be validated in 8-10 weeks.
Compliance & Regulatory Support
Our robust QMS implements best practice QC/QA measures for reliable results. As a CLIA-certified, CAP-accredited, and NYSDOH-licensed lab, we comply with FDA regulations and are preparing for ISO certification.
We support clients with reviews of the biomarker sections of INDs and study protocols, and participation in regulatory meetings.
NETest® 2.0 & PROSTest®
NETs and prostate cancer are different types of cancers, but they intersect through neuroendocrine differentiation in prostate adenocarcinoma.
Prolonged androgen deprivation therapy (ADT) for advanced prostate cancer can induce this differentiation, resulting in a more aggressive and treatment-resistant form of cancer with a poor prognosis.
Diagnosing neuroendocrine prostate cancer (NEPC), which occurs in 30-40% of castration-treated prostate cancer cases, typically requires a tissue biopsy and immunohistochemical staining for neuroendocrine markers.
Advanced imaging techniques, such as PET scans with specific tracers, may also help identify neuroendocrine lesions.
There is a significant unmet need for a reliable liquid biopsy method to detect neuroendocrine differentiation caused by long-term hormonal therapy. An ideal biomarker could enhance diagnostic, prognostic, and therapeutic approaches, particularly for managing advanced and treatment-resistant prostate cancer.
Using NETest® alongside PROSTest® can address these critical needs effectively.
